See more : GD Entertainment & Technology, Inc. (GDET) Income Statement Analysis – Financial Results
Complete financial analysis of Mallinckrodt plc (MNK) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Mallinckrodt plc, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Sanofi (SNY) Income Statement Analysis – Financial Results
- Waste Recovery Technology Inc. (6894.TWO) Income Statement Analysis – Financial Results
- Uoriki Co., Ltd. (7596.T) Income Statement Analysis – Financial Results
- Talen Energy Corporation (TLNE) Income Statement Analysis – Financial Results
- Cydsa, S.A.B. de C.V. (CDSAF) Income Statement Analysis – Financial Results
Mallinckrodt plc (MNK)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.mallinckrodt.com
About Mallinckrodt plc
Mallinckrodt plc develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies in the United States, Europe, the Middle East, Africa, and internationally. It operates in two segments, Specialty Brands and Specialty Generics. The company markets branded pharmaceutical products for autoimmune and rare diseases in the areas of neurology, rheumatology, nephrology, ophthalmology, pulmonology, and oncology; immunotherapy and neonatal respiratory critical care therapies; analgesics; cultured skin substitutes; and gastrointestinal products. It offers Acthar Gel, a repository corticotropin injection for rheumatoid arthritis, infantile spasms, systemic lupus erythematosus, multiple sclerosis, systemic dermatomyositis, symptomatic sarcoidosis, severe acute and chronic allergic, and inflammatory diseases; INOmax, a vasodilator to enhance oxygenation and reduce the need for extracorporeal membrane oxygenation; Therakos photopheresis, an immunotherapy treatment platform; Amitiza for constipation; and StrataGraft for the treatment of adults with deep partial-thickness burns. The company is also developing Terlipressin for the treatment of hepatorenal syndrome; and SLN 501 is a ribonucleic acid silencing therap. In addition, it provides specialty generic drugs and active pharmaceutical ingredients. The company markets its branded products to physicians, respiratory therapists, pharmacists, pharmacy buyers, hospital procurement departments, ambulatory surgical centers, and specialty pharmacies. Mallinckrodt plc has collaboration with Silence Therapeutics plc to develop and commercialize ribonucleic acid interference drug targets. The company was founded in 1867 and is based in Dublin, Ireland.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.21B | 2.21B | 2.21B | 3.16B | 3.22B | 3.22B | 3.38B | 3.35B | 2.54B | 2.21B | 2.06B | 2.02B |
| Cost of Revenue | 1.32B | 1.32B | 1.54B | 1.74B | 1.74B | 1.57B | 1.53B | 1.49B | 1.34B | 1.18B | 1.09B | 1.11B |
| Gross Profit | 891.70M | 891.70M | 669.40M | 1.42B | 1.47B | 1.66B | 1.86B | 1.85B | 1.20B | 1.03B | 964.80M | 914.90M |
| Gross Profit Ratio | 40.37% | 40.37% | 30.24% | 44.95% | 45.75% | 51.41% | 54.87% | 55.38% | 47.36% | 46.62% | 46.92% | 45.25% |
| Research & Development | 205.20M | 205.20M | 290.80M | 349.40M | 361.10M | 277.30M | 262.20M | 185.10M | 166.90M | 166.50M | 144.10M | 141.50M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 581.80M | 581.80M | 884.10M | 831.00M | 834.10M | 920.90M | 925.30M | 1.17B | 842.10M | 611.40M | 551.70M | 532.50M |
| Other Expenses | 0.00 | 22.00M | 7.40M | 63.60M | 30.90M | 6.00M | -600.00K | 8.10M | 1.80M | 800.00K | 1.00M | 2.90M |
| Operating Expenses | 787.00M | 787.00M | 1.17B | 1.18B | 1.20B | 1.20B | 1.19B | 1.35B | 1.01B | 777.90M | 695.80M | 674.00M |
| Cost & Expenses | 2.10B | 2.10B | 2.72B | 2.92B | 2.94B | 2.76B | 2.71B | 2.85B | 2.35B | 1.96B | 1.79B | 1.78B |
| Interest Income | 1.90M | 1.90M | 5.90M | 9.50M | 8.20M | 4.60M | 1.30M | 1.00M | 1.50M | 300.00K | 400.00K | 200.00K |
| Interest Expense | -222.60M | 222.60M | 261.10M | 309.00M | 370.20M | 369.10M | 384.60M | 255.60M | 82.60M | 19.50M | 500.00K | 600.00K |
| Depreciation & Amortization | 328.90M | 675.80M | 885.20M | 951.10M | 852.10M | 808.30M | 834.50M | 672.50M | 275.90M | 139.60M | 130.90M | 119.80M |
| EBITDA | -723.50M | 804.40M | 393.00M | 1.27B | 1.17B | 468.70M | 1.50B | 1.18B | 473.30M | 254.30M | 401.30M | 363.80M |
| EBITDA Ratio | -32.76% | 36.42% | 17.76% | 40.01% | 36.30% | 14.55% | 44.45% | 35.27% | 18.63% | 11.50% | 19.52% | 17.99% |
| Operating Income | -1.05B | 128.60M | -492.20M | 314.10M | -3.72B | 420.10M | 617.30M | 461.80M | -284.10M | 148.70M | 235.20M | 240.70M |
| Operating Income Ratio | -47.65% | 5.82% | -22.24% | 9.93% | -115.71% | 13.04% | 18.26% | 13.80% | -11.18% | 6.72% | 11.44% | 11.91% |
| Total Other Income/Expenses | 222.60M | -958.40M | -468.60M | -1.91B | -331.10M | -358.50M | -383.90M | -246.50M | -79.30M | -18.40M | 900.00K | 2.50M |
| Income Before Tax | -829.80M | -829.80M | -960.80M | -1.59B | -4.05B | 61.60M | 233.40M | 215.30M | -363.40M | 130.30M | 236.10M | 243.20M |
| Income Before Tax Ratio | -37.57% | -37.57% | -43.41% | -50.32% | -126.01% | 1.91% | 6.90% | 6.43% | -14.30% | 5.89% | 11.48% | 12.03% |
| Income Tax Expense | -112.40M | -106.30M | 8.90M | -584.30M | -430.10M | -1.71B | -255.60M | -92.90M | -44.80M | 70.20M | 94.80M | 86.20M |
| Net Income | -717.40M | -723.50M | -969.70M | -1.01B | -3.61B | 2.13B | 643.70M | 324.70M | -319.30M | 61.10M | 134.60M | 150.70M |
| Net Income Ratio | -32.48% | -32.76% | -43.81% | -31.85% | -112.17% | 66.25% | 19.04% | 9.70% | -12.57% | 2.76% | 6.55% | 7.45% |
| EPS | -8.47 | -8.54 | -11.48 | -12.00 | -42.94 | 21.85 | 5.82 | 2.78 | -4.92 | 1.06 | 2.33 | 2.61 |
| EPS Diluted | -8.47 | -8.54 | -11.48 | -12.00 | -42.94 | 21.80 | 5.77 | 2.75 | -4.92 | 1.06 | 2.33 | 2.61 |
| Weighted Avg Shares Out | 84.70M | 84.70M | 84.50M | 83.90M | 84.00M | 97.70M | 110.60M | 115.80M | 64.90M | 57.70M | 57.70M | 57.70M |
| Weighted Avg Shares Out (Dil) | 84.70M | 84.70M | 84.50M | 83.90M | 84.00M | 97.90M | 111.50M | 117.20M | 64.90M | 57.80M | 57.70M | 57.70M |
Should You Buy Penny Stocks Right Now? 3 Reasons
Drugmaker Mallinckrodt in talks with hedge funds to avoid opioid settlements - WSJ
Hedge Funds Seek to Cut Off $1 Billion Meant for Opioid Victims
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Mallinckrodt plc of Class Action Lawsuit and Upcoming Deadline - MNK
Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Mallinckrodt plc (MNK)
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Mallinckrodt plc (MNK) Investors
INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Mallinckrodt plc (MNK) Investors
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Mallinckrodt plc (MNK) on Behalf of Investors
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Mallinckrodt plc (MNK) on Behalf of Investors
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Mallinckrodt plc of Class Action Lawsuit and Upcoming Deadline - MNK
Source: https://incomestatements.info
Category: Stock Reports